Compare Cadila Healthcare with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs STRIDES PHARMA SCIENCE - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE STRIDES PHARMA SCIENCE CADILA HEALTHCARE/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 29.2 16.3 179.4% View Chart
P/BV x 3.5 1.0 349.5% View Chart
Dividend Yield % 1.0 0.5 203.1%  

Financials

 CADILA HEALTHCARE   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-19
STRIDES PHARMA SCIENCE
Mar-18
CADILA HEALTHCARE/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs4321,147 37.7%   
Low Rs306642 47.7%   
Sales per share (Unadj.) Rs128.6317.2 40.5%  
Earnings per share (Unadj.) Rs18.57.8 236.4%  
Cash flow per share (Unadj.) Rs24.425.1 97.4%  
Dividends per share (Unadj.) Rs3.502.00 175.0%  
Dividend yield (eoy) %0.90.2 423.8%  
Book value per share (Unadj.) Rs101.5274.3 37.0%  
Shares outstanding (eoy) m1,023.7489.50 1,143.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.92.8 101.9%   
Avg P/E ratio x19.9114.0 17.5%  
P/CF ratio (eoy) x15.135.7 42.4%  
Price / Book Value ratio x3.63.3 111.6%  
Dividend payout %18.925.5 74.0%   
Avg Mkt Cap Rs m378,17080,058 472.4%   
No. of employees `00012.42.5 496.1%   
Total wages/salary Rs m21,2414,341 489.4%   
Avg. sales/employee Rs Th10,585.011,325.8 93.5%   
Avg. wages/employee Rs Th1,707.81,731.4 98.6%   
Avg. net profit/employee Rs Th1,526.5280.1 545.1%   
INCOME DATA
Net Sales Rs m131,65628,394 463.7%  
Other income Rs m2,011941 213.8%   
Total revenues Rs m133,66729,334 455.7%   
Gross profit Rs m29,7313,965 749.8%  
Depreciation Rs m5,9861,540 388.6%   
Interest Rs m1,9351,962 98.6%   
Profit before tax Rs m23,8211,403 1,697.6%   
Minority Interest Rs m4690-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m5,30397 5,450.2%   
Profit after tax Rs m18,987702 2,704.3%  
Gross profit margin %22.614.0 161.7%  
Effective tax rate %22.36.9 321.0%   
Net profit margin %14.42.5 583.2%  
BALANCE SHEET DATA
Current assets Rs m84,98124,836 342.2%   
Current liabilities Rs m73,42518,993 386.6%   
Net working cap to sales %8.820.6 42.7%  
Current ratio x1.21.3 88.5%  
Inventory Days Days7571 105.0%  
Debtors Days Days110113 96.6%  
Net fixed assets Rs m133,49334,289 389.3%   
Share capital Rs m1,024895 114.4%   
"Free" reserves Rs m102,83923,651 434.8%   
Net worth Rs m103,86324,546 423.1%   
Long term debt Rs m39,49715,513 254.6%   
Total assets Rs m234,83165,437 358.9%  
Interest coverage x13.31.7 776.1%   
Debt to equity ratio x0.40.6 60.2%  
Sales to assets ratio x0.60.4 129.2%   
Return on assets %8.94.1 218.8%  
Return on equity %18.32.9 639.1%  
Return on capital %18.36.9 265.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m48,40415,697 308.4%   
Fx outflow Rs m11,593735 1,576.4%   
Net fx Rs m36,81114,962 246.0%   
CASH FLOW
From Operations Rs m28,8231,871 1,540.8%  
From Investments Rs m-57,3875,826 -985.0%  
From Financial Activity Rs m18,846-10,157 -185.5%  
Net Cashflow Rs m-7,105-2,615 271.7%  

Share Holding

Indian Promoters % 74.8 27.7 270.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 37.8 22.0%  
FIIs % 5.9 8.6 68.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 25.9 42.5%  
Shareholders   44,069 56,241 78.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   WYETH LTD  IPCA LABS  JUBILANT LIFE SCIENCES  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 661 Points; Banking and Finance Stocks Witness Huge Selling(Closing)

Indian share markets fell sharply today, led by weak Asian equities as worries of new lockdowns to stem surging coronavirus cases kept investors cautious worldwide.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

These 3 Recent Events Will Impact the Price of Gold(Fast Profits Daily)

Jul 1, 2020

Recent developments in the bullion market may put some short term pressure on gold prices.

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jul 14, 2020 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - SANOFI INDIA COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS